Overview
Spherix’s coverage of the rheumatoid arthritis segment focuses on tracking brand usage and changes in the treatment paradigm with increasing interest in alternate mechanisms of action in the US and the EU5. We also provide detailed insights in patient characteristics that influence treatment switching decisions.
Services Available
Trending market evolution
Rheumatoid Arthritis (US) - quarterly, n=100
Rheumatoid Arthritis (EU) - semiannual, n=250
Exploring the patient journey
Biologic/Small Molecule Switching in RA (US) - n=1,000 patient charts
Biologic/Small Molecule Switching in RA (EU) - n=1,250 patient charts
Gauging impact of disruptive events
Multi-Specialty Impact of COVID-19 (US)